Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy : Who benefits?
Copyright © 2020 Elsevier B.V. All rights reserved..
Intravenous immunoglobulins (IVIg) represent an established cornerstone for the immunotherapy of chronic inflammatory demyelinating polyneuropathy (CIDP). Efficacy of IVIg for CIDP was proven in a large phase III trial. Yet, data on longer-term efficacy and effects in distinct subgroups are scarce. Our trial investigates the long-term efficacy of IVIg treatment in CIDP patients. In this observational real-world study, we retrospectively analyzed 49 CIDP patients receiving continuous IVIg treatment with a mean initial dosage of 87 g (1 g/kg body weight) every 4 weeks over a mean time of 45 months between 2010 and 2018. INCAT-Scores before the start of treatment and at the end of the observation period were compared. Over the observation period, IVIg treatment led to a median improvement of one INCAT score point. Subgroup analyses revealed a more pronounced improvement of INCAT scores in female CIDP patients, individuals with relapsing disease courses, patients with more pronounced motor impairment (higher initial INCAT scores) and in the cohort without need for concomitant other immunotherapies. These data argue for sustained beneficial effects of longer-term immunotherapy with IVIg in CIDP, particularly in females and relapsing disease forms with higher disease activity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:419 |
|---|---|
| Enthalten in: |
Journal of the neurological sciences - 419(2020) vom: 15. Dez., Seite 117169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Terhoeven, Pauline [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic inflammatory demyelinating polyneuropathy |
|---|
| Anmerkungen: |
Date Completed 14.05.2021 Date Revised 14.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jns.2020.117169 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31605819X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31605819X | ||
| 003 | DE-627 | ||
| 005 | 20231225160246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jns.2020.117169 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM31605819X | ||
| 035 | |a (NLM)33035867 | ||
| 035 | |a (PII)S0022-510X(20)30505-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Terhoeven, Pauline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy |b Who benefits? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.05.2021 | ||
| 500 | |a Date Revised 14.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Intravenous immunoglobulins (IVIg) represent an established cornerstone for the immunotherapy of chronic inflammatory demyelinating polyneuropathy (CIDP). Efficacy of IVIg for CIDP was proven in a large phase III trial. Yet, data on longer-term efficacy and effects in distinct subgroups are scarce. Our trial investigates the long-term efficacy of IVIg treatment in CIDP patients. In this observational real-world study, we retrospectively analyzed 49 CIDP patients receiving continuous IVIg treatment with a mean initial dosage of 87 g (1 g/kg body weight) every 4 weeks over a mean time of 45 months between 2010 and 2018. INCAT-Scores before the start of treatment and at the end of the observation period were compared. Over the observation period, IVIg treatment led to a median improvement of one INCAT score point. Subgroup analyses revealed a more pronounced improvement of INCAT scores in female CIDP patients, individuals with relapsing disease courses, patients with more pronounced motor impairment (higher initial INCAT scores) and in the cohort without need for concomitant other immunotherapies. These data argue for sustained beneficial effects of longer-term immunotherapy with IVIg in CIDP, particularly in females and relapsing disease forms with higher disease activity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic inflammatory demyelinating polyneuropathy | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Intravenous immunoglobulins | |
| 650 | 4 | |a Long-term effect | |
| 650 | 4 | |a Polyneuritis | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 700 | 1 | |a Seybold, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Utz, Kathrin S |e verfasserin |4 aut | |
| 700 | 1 | |a Nickel, Florian T |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, De-Hyung |e verfasserin |4 aut | |
| 700 | 1 | |a Linker, Ralf A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the neurological sciences |d 1964 |g 419(2020) vom: 15. Dez., Seite 117169 |w (DE-627)NLM000061956 |x 1878-5883 |7 nnns |
| 773 | 1 | 8 | |g volume:419 |g year:2020 |g day:15 |g month:12 |g pages:117169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jns.2020.117169 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 419 |j 2020 |b 15 |c 12 |h 117169 | ||